Quisqualate injection into the nucleus basalis magnocellularis produces seizure-related brain damage that is prevented by MK-801.
Quisqualate (Quis) and other excitotoxins such as ibotenate and N-methyl aspartate, have been used to destroy neurons in the area of the nucleus basalis magnocellularis (NBM) in order to study the relationship between loss of cholinergic neurons in the basal forebrain and various behavioral deficits, including learning and memory impairments. The results of several studies suggest that although Quis NBM lesions may produce greater depletions in cortical choline acetyltransferase levels than ibotenate lesions, the learning/memory deficits tend to be milder following Quis lesions. In these studies, it was often assumed that the lesions induced by Quis were restricted to the local vicinity of the injection. However, in the present study, we found that an injection of Quis into the NBM/substantia inominata (SI) region often induces limbic seizures and disseminated brain damage. Specifically, we found that an injection of Quis into the NBM/SI area of female rats at a dose (120 nmol) used by others in previous behavioral studies produced massive damage in areas distant from the lesion site, particularly in the amygdala and piriform cortex. This disseminated damage occurred in 50% of the rats treated with Quis, was typically more severe than damage at the injection site, and was often accompanied by equally severe "mirror" lesions in the contralateral amygdala and piriform cortex. Injecting rats with MK-801 (1 mg/kg) 30 min before the Quis injection protected against the disseminated damage. These data underscore the need for careful histological evaluation of excitotoxic lesions and for caution in interpreting the relationship between altered transmitter markers and learning/memory impairment seen following these lesions.
Wozniak
D F
DF
Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110.
Huss
J
J
Olney
J W
JW
D000679:Amygdala / Q000187:drug effects / Q000473:pathology*; D000818:Animals; D001925:Brain Damage, Chronic / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D016291:Dizocilpine Maleate / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D008032:Limbic System / Q000187:drug effects / Q000473:pathology*; D009043:Motor Activity / Q000187:drug effects*; D016318:Quisqualic Acid / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D013238:Stereotaxic Techniques; D013377:Substantia Innominata / Q000187:drug effects / Q000473:pathology*
D016291:Dizocilpine Maleate; D016318:Quisqualic Acid